Biotech · Private company
Celgene
Track this companyFree. Adds Celgene to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs30From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline30
- AbirateronePhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ACE-536Phase 3 · Myeloproliferative DisordersClinicalTrials.gov · fetched Nov 12, 2026
- BMS-986365Phase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- BortezomibPhase 3 · Relapsed or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 3 · Relapsed or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Gene-modified (GM) T cell therapyPhase 3 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- mezigdomidePhase 3 · Relapsed or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 3 · Relapsed or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Predinsone/PrednisolonePhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ACE-536Phase 2 · Beta-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- BMS-986368Phase 2 · Multiple Sclerosis SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- BMS-986368Phase 2 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DoxorubicinPhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- ElranatamabPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- GolcadomidePhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- MezigdomidePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- VincristinePhase 2 · Lymphoma, FollicularClinicalTrials.gov · fetched Nov 12, 2026
- CC-220Phase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- DoxorubicinPhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- IrafamdastatPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- VincristinePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisPHASE3 · NOT_YET_RECRUITING · started Feb 3, 2027ClinicalTrials.gov NCT07335562 · fetched Nov 12, 2026
- A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult ParticipantsPHASE1 · RECRUITING · started Oct 6, 2026ClinicalTrials.gov NCT07837115 · fetched Nov 12, 2026
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMPHASE3 · RECRUITING · started Aug 31, 2026ClinicalTrials.gov NCT07624513 · fetched Nov 12, 2026
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaPHASE1_PHASE2 · RECRUITING · started Oct 7, 2025ClinicalTrials.gov NCT06988488 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePHASE2 · RECRUITING · started Jun 9, 2025ClinicalTrials.gov NCT06808984 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPHASE2 · RECRUITING · started Jun 5, 2025ClinicalTrials.gov NCT06782490 · fetched Nov 12, 2026
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 13, 2025ClinicalTrials.gov NCT06764485 · fetched Nov 12, 2026
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)PHASE3 · RECRUITING · started Mar 12, 2025ClinicalTrials.gov NCT06615479 · fetched Nov 12, 2026
- ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaPHASE1 · RECRUITING · started Nov 1, 2024ClinicalTrials.gov NCT06518551 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 30, 2024ClinicalTrials.gov NCT06425302 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 28, 2024ClinicalTrials.gov NCT06220201 · fetched Nov 12, 2026
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)PHASE3 · RECRUITING · started Sep 20, 2022ClinicalTrials.gov NCT05519085 · fetched Nov 12, 2026
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 15, 2021ClinicalTrials.gov NCT04884035 · fetched Nov 12, 2026
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 25, 2021ClinicalTrials.gov NCT04717414 · fetched Nov 12, 2026
- Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 10, 2020ClinicalTrials.gov NCT04113018 · fetched Nov 12, 2026
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaPHASE2 · RECRUITING · started Nov 7, 2019ClinicalTrials.gov NCT04143724 · fetched Nov 12, 2026
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPHASE2_PHASE3 · RECRUITING · started Jul 19, 2018ClinicalTrials.gov NCT03435796 · fetched Nov 12, 2026
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromePHASE2 · RECRUITING · started Jan 17, 2018ClinicalTrials.gov NCT03383575 · fetched Nov 12, 2026
- Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous SystemPHASE2 · RECRUITING · started Oct 6, 2017ClinicalTrials.gov NCT03270059 · fetched Nov 12, 2026
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced RemissionPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 1, 2017ClinicalTrials.gov NCT03059485 · fetched Nov 12, 2026
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 7, 2017ClinicalTrials.gov NCT02886065 · fetched Nov 12, 2026
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 21, 2017ClinicalTrials.gov NCT02992522 · fetched Nov 12, 2026
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · RECRUITING · started Feb 9, 2017ClinicalTrials.gov NCT02977780 · fetched Nov 12, 2026
- Lenalidomide for Adult Histiocyte DisordersPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 1, 2015ClinicalTrials.gov NCT02523040 · fetched Nov 12, 2026
- Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 2, 2015ClinicalTrials.gov NCT02270814 · fetched Nov 12, 2026